Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Souvie Biodelivery
AddedFeb 18, 2024
UpdatedJun 18, 2026
Souvie Biodelivery

Souvie Biodelivery

Angel

Souvie Biodelivery: Pioneering nanotechnology for innovative drug delivery solutions.

HQ
Tucson, AZ, US
Founded
2018
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize drug delivery, Souvie Biodelivery leverages nanotechnology to create advanced drug delivery platforms. The company focuses on developing engineered exosomes for tissue and site-specific active pharmaceutical ingredient (API) delivery. Their innovative solutions aim to enhance biocompatibility, reduce immunogenicity, and protect APIs from degradation, thereby increasing specificity and efficacy to minimize adverse drug reactions. Souvie Biodelivery targets niche markets within the pharmaceutical industry, aiming to set new standards in therapeutic delivery.

Souvie Biodelivery has garnered attention from notable investors and industry experts due to its pioneering approach in nanotechnology. The company has achieved significant milestones, including the successful patenting of its novel drug delivery platforms. Its impact is evident in the potential to transform how drugs are administered, offering safer and more effective treatments. Through its cutting-edge technology, Souvie Biodelivery is poised to make substantial contributions to the field of pharmaceutical sciences and patient care.

Souvie Biodelivery - Similar Companies

Nanotransfer logo

Nanotransfer

nanotransfer.bio

NMB Therapeutics logo

NMB Therapeutics

Nano PharmaSolutions logo

Nano PharmaSolutions

Advanced NanoTherapies logo

Advanced NanoTherapies

Mantra Bio logo

Mantra Bio

mantrabio.com

Phoreus Biotechnology logo

Phoreus Biotechnology

phoreusbiotech.com

Tiny Cargo logo

Tiny Cargo

tinycargo.com

Leonardo Biosystems logo

Leonardo Biosystems

Nano RED logo

Nano RED

Syntis Bio logo

Syntis Bio

syntis.bio

Atom Bioworks logo

Atom Bioworks

atombioworks.com

Cytonus Therapeutics logo

Cytonus Therapeutics

cytonus.com

NanoMedical Systems logo

NanoMedical Systems

nanomedsys.com

Control Delivery Systems logo

Control Delivery Systems

Revive Biotechnology logo

Revive Biotechnology

revivebiotech.com

Souvie Biodelivery - Quick Facts

Who are Souvie Biodelivery's competitors?

Companies similar to Souvie Biodelivery include Nanotransfer, NMB Therapeutics, Nano PharmaSolutions and Advanced NanoTherapies.

When was Souvie Biodelivery founded?

Souvie Biodelivery was founded in 2018.

Where is Souvie Biodelivery's headquarters located?

Souvie Biodelivery's headquarters is located in Tucson, AZ, US.

When was Souvie Biodelivery's last funding round?

Souvie Biodelivery's most recent funding round was for $225k (USD) in February 2021.

How much has Souvie Biodelivery raised to-date?

As of Feb 3, 2021, Souvie Biodelivery has raised a total of $225k (USD).

How many employees does Souvie Biodelivery have?

Souvie Biodelivery has 1 employee as of Feb 4, 2024.

Souvie Biodelivery - Classification

Ownership
  • Private
Technology
  • Nanotechnology
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Delivery
Tags
  • Biotech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations